[PMID]: | 28708284 |
[Au] Autor: | Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C |
[Ad] Endereço: | Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University of Kiel, Kiel, Germany. |
[Ti] Título: | CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells. |
[So] Source: | Scand J Immunol;86(4):196-206, 2017 Oct. |
[Is] ISSN: | 1365-3083 |
[Cp] País de publicação: | England |
[La] Idioma: | eng |
[Ab] Resumo: | Human γδ T cells are innate-like T cells which are able to kill a broad range of tumour cells and thus may have potential for cancer immunotherapy. The activating receptor natural killer group 2 member D (NKG2D) plays a key role in regulating immune responses driven by γδ T cells. Here, we explored whether recombinant immunoligands consisting of a CD20 single-chain fragment variable (scFv) linked to a NKG2D ligand, either MHC class I chain-related protein A (MICA) or UL16 binding protein 2 (ULBP2), could be employed to engage γδ T cells for tumour cell killing. The two immunoligands, designated MICA:7D8 and ULBP2:7D8, respectively, enhanced cytotoxicity of ex vivo-expanded γδ T cells against CD20-positive lymphoma cells. Both Vδ1 and Vδ2 γδ T cells were triggered by MICA:7D8 or ULBP2:7D8. Killing of CD20-negative tumour cells was not induced by the immunoligands, indicating their antigen specificity. MICA:7D8 and ULBP2:7D8 acted in a dose-dependent manner and induced cytotoxicity at nanomolar concentrations. Importantly, chronic lymphocytic leukaemia (CLL) cells isolated from patients were sensitized by the two immunoligands for γδ T cell cytotoxicity. In a combination approach, the immunoligands were combined with bromohydrin pyrophosphate (BrHPP), an agonist for Vδ2 γδ T cells, which further enhanced the efficacy in target cell killing. Thus, employing tumour-directed recombinant immunoligands which engage NKG2D may represent an attractive strategy to enhance antitumour cytotoxicity of γδ T cells. |
[Mh] Termos MeSH primário: |
Antígenos CD20/metabolismo Citotoxicidade Imunológica Imunoterapia/métodos Linfoma/terapia Subfamília K de Receptores Semelhantes a Lectina de Células NK/metabolismo Anticorpos de Cadeia Única/uso terapêutico Linfócitos T/fisiologia
|
[Mh] Termos MeSH secundário: |
Antígenos CD20/imunologia Difosfatos/uso terapêutico Quimioterapia Combinada Proteínas Ligadas por GPI/genética Antígenos de Histocompatibilidade Classe I/genética Seres Humanos Imunização Peptídeos e Proteínas de Sinalização Intercelular/genética Linfoma/imunologia Receptores de Antígenos de Linfócitos T gama-delta/metabolismo Anticorpos de Cadeia Única/genética Células Tumorais Cultivadas
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (Antigens, CD20); 0 (Diphosphates); 0 (GPI-Linked Proteins); 0 (Histocompatibility Antigens Class I); 0 (Intercellular Signaling Peptides and Proteins); 0 (KLRK1 protein, human); 0 (MHC class I-related chain A); 0 (NK Cell Lectin-Like Receptor Subfamily K); 0 (Receptors, Antigen, T-Cell, gamma-delta); 0 (Single-Chain Antibodies); 0 (ULBP2 protein, human); 0 (bromohydrin pyrophosphate) |
[Em] Mês de entrada: | 1710 |
[Cu] Atualização por classe: | 171013 |
[Lr] Data última revisão:
| 171013 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170715 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1111/sji.12581 |
|
|